Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 5
2021 1
2022 2
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Girard N, et al. J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307040 Free article.
INTRODUCTION: The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients with unresectable, stage III NSCLC and no disease progression after definitive chemoradiotherapy (CRT). ...Overall, 16.5% …
INTRODUCTION: The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients wit …
Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR.
Park CK, Oh HJ, Kim YC, Kim YH, Ahn SJ, Jeong WG, Lee JY, Lee JC, Choi CM, Ji W, Song SY, Choi J, Lee SY, Kim H, Lee SY, Park J, Yoon SH, Joo JH, Oh IJ. Park CK, et al. J Thorac Oncol. 2023 Aug;18(8):1042-1054. doi: 10.1016/j.jtho.2023.04.008. Epub 2023 Apr 20. J Thorac Oncol. 2023. PMID: 37085032 Free article.
INTRODUCTION: This study aimed to investigate real-world evidence for efficacy and safety of durvalumab consolidation (DC) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC. ...CONCLUSIONS: Compared with t …
INTRODUCTION: This study aimed to investigate real-world evidence for efficacy and safety of durvalumab consolidatio
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, Ahn MJ, Pyo H, Ahn YC, Park K. Jung HA, et al. Lung Cancer. 2020 Aug;146:23-29. doi: 10.1016/j.lungcan.2020.05.035. Epub 2020 May 31. Lung Cancer. 2020. PMID: 32505077
OBJECTIVES: The PACIFIC study demonstrated the benefits of durvalumab consolidation on progression-free survival (PFS) and overall survival (OS) among patients with unresectable locally advanced non-small-cell lung cancer (LA-NSCLC …
OBJECTIVES: The PACIFIC study demonstrated the benefits of durvalumab consolidation on progression-free survival (PFS) and ove …
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH, Chiu TH, Wang CC, Chang WC, Huang AC, Liu CY, Wang CL, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Chu CH, et al. Thorac Cancer. 2020 Jun;11(6):1541-1549. doi: 10.1111/1759-7714.13426. Epub 2020 Apr 13. Thorac Cancer. 2020. PMID: 32281272 Free PMC article.
BACKGROUND: Treatment for stage III non-small cell lung cancer (NSCLC) of unresectable disease mainly involves concurrent chemoradiation (CRT). Post-CRT consolidation treatment with durvalumab is a major therapeutic a …
BACKGROUND: Treatment for stage III non-small cell lung cancer (NSCLC) of unresectable dise …
Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer.
Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Ohtsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Hirai T, Mizowaki T; Kyoto Radiation Oncology Study Group (KROSG). Kishi N, et al. J Radiat Res. 2023 Jan 20;64(1):142-153. doi: 10.1093/jrr/rrac057. J Radiat Res. 2023. PMID: 36149029 Free PMC article.
Chemoradiotherapy followed by consolidation durvalumab (CCRT+D) improves survival in patients with stage III non-small-cell lung cancer (NSCLC). ...We conducted a multicenter, retrospective study in Japan. Pati
Chemoradiotherapy followed by consolidation durvalumab (CCRT+D) improves survival in patients with stage III
Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P, Borsoi L, Fornaro G, Jommi C, Grossi F, Costa F. Armeni P, et al. Clin Ther. 2020 May;42(5):830-847. doi: 10.1016/j.clinthera.2020.03.012. Epub 2020 Apr 27. Clin Ther. 2020. PMID: 32354495
PURPOSE: The aim of this study was to evaluate the cost-effectiveness and net monetary benefit of durvalumab consolidation therapy compared with no consolidation therapy after chemoradiotherapy in patients with stage III non-sma
PURPOSE: The aim of this study was to evaluate the cost-effectiveness and net monetary benefit of durvalumab consolidation the …
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond.
Fitzpatrick O, Naidoo J. Fitzpatrick O, et al. Lung Cancer (Auckl). 2021 Nov 2;12:123-131. doi: 10.2147/LCTT.S305466. eCollection 2021. Lung Cancer (Auckl). 2021. PMID: 34754256 Free PMC article. Review.
Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non-small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown to be effica …
Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non-small
Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.
Horinouchi H, Atagi S, Oizumi S, Ohashi K, Kato T, Kozuki T, Seike M, Sone T, Sobue T, Tokito T, Harada H, Maeda T, Mio T, Shirosaka I, Hattori K, Shin E, Murakami H. Horinouchi H, et al. Cancer Med. 2020 Sep;9(18):6597-6608. doi: 10.1002/cam4.3306. Epub 2020 Jul 30. Cancer Med. 2020. PMID: 32730697 Free PMC article.
There are limited real-world data on the treatment practices, outcomes, and safety of chemoradiotherapy (CRT) alone in potential candidates for immune checkpoint inhibitors (ICI) for unresectable non-small cell lung cance
There are limited real-world data on the treatment practices, outcomes, and safety of chemoradiotherapy (CRT) al …
Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience.
Borghetti P, Volpi G, Facheris G, Cossali G, Mataj E, La Mattina S, Singh N, Imbrescia J, Bonù ML, Tomasini D, Vitali P, Greco D, Bezzi M, Melotti F, Benvenuti M, Borghesi A, Grisanti S, Buglione di Monale E Bastia M. Borghetti P, et al. Front Oncol. 2023 Jul 4;13:1208204. doi: 10.3389/fonc.2023.1208204. eCollection 2023. Front Oncol. 2023. PMID: 37469420 Free PMC article.
INTRODUCTION: The standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by consolidation durvalumab as shown in the PACIFIC trial. The …
INTRODUCTION: The standard of care for patients with unresectable stage III non-small cell lung
Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study.
Park JE, Hong KS, Choi SH, Lee SY, Shin KC, Jang JG, Kwon YS, Park SH, Choi KJ, Jung CY, Eom JS, Kim S, Seol HY, Kim J, Kim I, Park JH, Kim TH, Ahn JH. Park JE, et al. Clin Lung Cancer. 2024 Feb 17:S1525-7304(24)00017-2. doi: 10.1016/j.cllc.2024.02.006. Online ahead of print. Clin Lung Cancer. 2024. PMID: 38503590
BACKGROUND: The PACIFIC trial demonstrated survival benefit of durvalumab after concurrent chemoradiotherapy (CCRT) in unresectable stage III non-small-cell lung cancer. Data on the effectiveness and safety of …
BACKGROUND: The PACIFIC trial demonstrated survival benefit of durvalumab after concurrent chemoradiotherapy (CCRT) in unresec …
14 results